---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-001973"
form_type: "8-K"
ticker: "RLAY"
cik: "0001812364"
company_name: "Relay Therapeutics, Inc."
filed_at: "2022-02-24T23:59:59+00:00"
generated_at: "2026-06-27T04:59:54.912187+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Relay Therapeutics reports FY2021 net loss of $363.9M; cash $958M into 2025

## Summary
- Q4 net loss $67.5M vs net income $35.3M in Q4 2020; full-year net loss $363.9M ($3.82 loss per share).
- Cash, cash equivalents and investments $958.1M at Dec 31 2021, expected to fund operations into at least 2025.
- R&D expenses $172.7M for FY2021 (up from $99.9M in FY2020), driven by clinical trial and employee costs.
- Announced interim data for RLY-4008 (FGFR2 inhibitor) showing tumor shrinkage in all six treatment-naïve FGFR2 fusion+ cholangiocarcinoma patients.
- Dosed first patient in RLY-2608 (pan-mutant PI3Kα inhibitor) first-in-human trial; FDA granted orphan drug designation for RLY-4008 in cholangiocarcinoma.

## SEC filing metadata
- accession: 0000950170-22-001973
- form_type: 8-K
- ticker: RLAY
- cik: 0001812364
- company_name: Relay Therapeutics, Inc.
- filed_at: 2022-02-24T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1812364/000095017022001973/0000950170-22-001973-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1812364/000095017022001973/rlay-20220224.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-001973
- JSON: https://secwatch.observer/filing/0000950170-22-001973.json
- Plain text: https://secwatch.observer/filing/0000950170-22-001973.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.